Efficacy of a proprietary compound B in a humanized mouse model of psoriasis

Efficacy of a proprietary compound B in a humanized mouse model of psoriasis - Pre-clinical efficacy of compound B in psoriasis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON34173

Enrollment

Registered

2010-05-20

Start date

2010-07-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

flaking disease psoriasis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Psoriasis patients: Adults (m/f) with a mild form of psoriasis vulgaris (PASI score of maximal 6). Patients are allowed to use localcorticosteriods or ointments to prevent dry skin (see appendix 2).

Exclusion criteria

Exclusion criteria: Psoriasis patients: These patients have not received light therapy or another form of systemic treatment (methotrexaat, cyclosporin A,anti-TNF treatments). Gender or age of the adults are not a exclusion criteria.(see appendix 2)

Design outcomes

Primary

Measure	Time frame
Effect on the psoriatic process is tested by histology and immuno-histochemical techniques in the transplanted biopsies. Main read-out epidermal thickness.	—

Secondary

Measure	Time frame
Serum markers in blood of transplanted mice will be studied together with markers on culture cells from psoriasis patients.	—

Countries

Netherlands

Outcome results